Institutional members access full text with Ovid®

Share this article on:

Homogeneous Staining Regions for Cyclin D1, a Marker of Poor Prognosis in Malignant Melanoma

Gammon, Bryan MD*; Ali, Liaqat MD; Guitart, Joan MD*; Gerami, Pedram MD*

The American Journal of Dermatopathology: July 2012 - Volume 34 - Issue 5 - p 487–490
doi: 10.1097/DAD.0b013e31823894f8
Original Study

Abstract: Homogeneous staining regions (HSRs) have been previously shown to confer a worse prognosis in solid tumors and myelodysplastic syndromes. We previously reported a single case of melanoma with HSR for cyclin D1 and postulated that HSR for cyclin D1 is an independent poor prognostic indicator. Herein, we report 7 cases of melanoma with HSR for cyclin D1. The cases occurred in elderly men and women with an average age of 65 years. Three cases occurred in areas of intermittent sun exposure, 2 cases occurred in chronically sun-damaged areas, and 2 cases were acral. HSR correlated with aggressive histology. The average Breslow depth was 2.7 mm (range, 1–11 mm), the average mitotic index was 5.1 per square millimeter, and 5 of the 7 cases were ulcerated. Clinical follow-up was available for 6 of the 7 cases. Five of the 6 cases for which clinical follow-up was available metastasized, and 1 patient died of metastatic melanoma. Three cases with metastatic disease occurred in primary melanomas with lower Breslow depths, ranging from 1.0 to 1.4 mm. These additional cases of melanoma with an aggressive clinical course provide further evidence of the prognostic significance of HSR for cyclin D1 in melanoma. Larger cohort studies are needed to validate this observation.

*Department of Dermatology, School of Medicine, Northwestern University, Chicago, IL

Department of Pathology, State University of New York, Buffalo, NY.

Supported in part by the IDP Foundation, the Dermatology Foundation, and the IL Division of the American Cancer Society and was not funded by Neogenomics or Abbott Molecular, Inc.

Dr P. Gerami has served as a consultant to and received honoraria from Abbott Molecular, Inc, and Neogenomics.

Reprints: Pedram Gerami, MD, Northwestern University, Chicago, IL 676 N St. Clair Suite 1600, Chicago, IL 60611 (e-mail:

© 2012 Lippincott Williams & Wilkins, Inc.